ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / SGMT / insiders
WVE (22) APMD (43) DSGN (33) AVBP (29) ⌘ Pro Terminal →

Sagimet Biosciences Inc. (Series A) (SGMT) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$9.92 -4.89% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.81

Sagimet Biosciences Inc. (Series A) (SGMT) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $699.7M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SGMT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SGMT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Sagimet Biosciences Inc. (Series A) (NASDAQ: SGMT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $9.92 (-4.89% 1D, market cap $699.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, SGMT ranks #439 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SGMT compare to WVE and APMD in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SGMT carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, WVE (Wave Life Sciences Inc.) holds a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $708.1M) and APMD (Apnimed Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC —, cap $682.7M). Among the 5-stock peer group, SGMT leads on earnings multiple (N/A) while DSGN leads on capital efficiency (-32.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SGMT?
▼

Per SGMT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001400118), Sagimet Biosciences Inc. (Series A) generated $159.3M in revenue (+4.5% YoY), -$51.0M in net income, and -$45.6M in free cash flow against $116.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $9.81 (-1.07%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510041
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Cash (7)Whales (11)SEC (10)Macro (10)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-7.7% Base Target
$12 Bull$9 Base$7 Bear
📬 FREE SGMT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SGMT)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (41/100 Composite)
🔍 WHY SGMT SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (27% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
33
Grade E$7.98+22.1% Next Q
Q2 (-2Q)
36
Grade E$9.74+7% Next Q
Q3 (-1Q)
38
Grade E$10.42-4.8% Next Q
Current
41
Grade D-$9.92-7.2% Hist 90D α
Trajectory: E (33) → D- (41)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SGMT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SGMT currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.93) and Max Pain ($10.42) forces dealer call-delta covering toward $12.02.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SGMT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SGMT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 41%NO 59%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

SGMT Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (SGMT)

No recent open-market Form 4 cluster sales or emergency dumps flagged on SGMT. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SGMT)

  • ✓Walkthrough of SGMT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
SGMT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +25.57%▲ ASCENDING CHANNEL
2026-11-03O $10.43H $10.43L $9.92C $9.92VOL 989.2K
RES: $13.33SUP: $7.79SMA50: $9.93SMA200: $7.54
$11.85$10.20$8.56$6.91$5.27RES $13.33SUP $7.79$9.922026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SGMT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SGMT Butterfly Map → + Track SGMT →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +4.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SGMT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SGMT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SGMT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SGMT)

Health Care Rank #439 of 1015 ⚔️ WVE vs SGMT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SGMT vs. WVE, APMD, DSGN, AVBP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Sagimet Biosciences Inc. (Series A) (SGMT) ranks #439 by composite RQD confidence (41/100, grade D-) and #395 by equity capitalization ($699.7M). Within this direct 5-issuer industry benchmark cohort, SGMT leads on earnings valuation at N/A trailing P/E, while DSGN leads on capital efficiency and profitability with -32.1% ROIC and — gross margin. APMD currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with SGMT at 41/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SGMT ACTIVE
Sagimet Biosciences Inc. (Series A)
D- 41/100 — — -35.0% -4.89% $699.7M Benchmark Subject
WVE
Wave Life Sciences Inc.
E 22/100 — — -35.0% -1.10% $708.1M /wve-vs-sgmt →
APMD
Apnimed Inc.
D- 43/100 — — — -5.42% $682.7M /apmd-vs-sgmt →
DSGN
Design Therapeutics Inc.
E 33/100 — — -32.1% -3.44% $668.4M /dsgn-vs-sgmt →
AVBP
ArriVent BioPharma Inc.
E 29/100 — — -35.0% -6.77% $733.2M /avbp-vs-sgmt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001400118 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Sagimet Biosciences Inc. (Series A) (SGMT) reported GAAP revenue of $159.3M (+4.5% vs. FY2024 revenue of $152.5M , and +7864.5% cumulative change since FY2023) , GAAP net income of -$51.0M, operating cash flow of -$45.6M, and free cash flow of -$45.6M (-7.6% YoY). On the balance sheet, SGMT closed FY2025 with $116.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $159.3M -$51.0M -$45.6M -$45.6M $116.5M —
FY2024 (FY) 2024-12-31 $152.5M -$45.6M -$42.4M -$42.4M $160.3M —
FY2023 (FY) 2023-12-31 $2.0M -$27.9M -$23.8M -$23.8M — —

3. SGMT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SGMT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Sagimet Biosciences Inc. (Series A) (NASDAQ: SGMT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $9.92 (-4.89% 1D, market cap $699.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, SGMT ranks #439 in composite RQD confidence.

How does SGMT compare to WVE and APMD in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SGMT carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, WVE (Wave Life Sciences Inc.) holds a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $708.1M) and APMD (Apnimed Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC —, cap $682.7M). Among the 5-stock peer group, SGMT leads on earnings multiple (N/A) while DSGN leads on capital efficiency (-32.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SGMT?

Per SGMT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001400118), Sagimet Biosciences Inc. (Series A) generated $159.3M in revenue (+4.5% YoY), -$51.0M in net income, and -$45.6M in free cash flow against $116.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SGMT trading relative to its 50-day, 200-day, and 52-week technical levels?

SGMT last traded at $9.92 (-4.89% on volume of 989,160 shares), positioning the stock -0.10% below its 50-day simple moving average ($9.93) and +31.56% above its 200-day simple moving average ($7.54). Across its 52-week range of $4.50 to $11.45, SGMT sits at the 78.0% percentile with a 14-day RSI of 52.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($8.68 to $11.16).

Direct Sub-Reports: SGMT RQD Cockpit SGMT 12M Forecast SGMT Earnings & Move SGMT Dividends & DRIP SGMT Insiders & 13F SGMT Whale Options SGMT Profit Sankey SGMT News & Why
ROARABLE RATING BRIEF • RQD 41/100 (D-) ✓ SEC XBRL & RQD VERIFIED

SGMT — Sagimet Biosciences Inc. (Series A): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Sagimet Biosciences Inc. (Series A) (SGMT) earns a live Roarable RQD composite score of 41/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $9.92 (-4.89% 1D, market capitalization $699.7M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -6.21%.
  • Whale 13F & Options Flow (11/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

And profile, Sagimet Biosciences Inc. (Series A) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Reported revenue is — for FY 2025 and FY 2024, with $2.0M reported for FY 2023..7B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Sagimet Biosciences Inc. (Series A) (SGMT) reported $159.3M in annual revenue (up from $152.5M in FY2024, +4.5% YoY) and -$51.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.0M revenue, -$27.9M net income) through FY2025, SGMT scaled operating cash flow to -$45.6M and free cash flow to -$45.6M, backed by $116.5M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 41/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -6.21% and institutional whale pillar of 11/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 11/20, sustained execution supports upside toward the upper end of the $4.50 – $11.45 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), SGMT carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can SGMT sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $159.3M and free cash flow of -$45.6M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is SGMT's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SGMT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Sagimet Biosciences Inc. (Series A) (SGMT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SGMT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SGMT Bull vs. Bear Conversation Board — What's Your Call at $9.92?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SGMT 🐻 33% BEARISH CONVICTION
1. Pick Your Side on SGMT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $12.10 (+22.0%)
📌 Pinned Debate

Institutional accumulation and options positioning earn the highest pillar score (15/20), signaling some institutional interest despite

Picked up a starter position in SGMT in my $100K Virtual Cash book at $9.92. Institutional accumulation and options positioning earn the highest pillar score (15/20), signaling some institutional interest despite weak fundamentals.. Trading inside a $4.50–$11.45 52-week range with -6.21% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

ArenaChamp_24 🐂 BULL

@QuantViper Agree on the RQD 41/100 quality, though with 1.0 beta I'm scaling in with half-size at $9.92 and keeping dry powder in case we test $9.23.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $8.23 (-17.0%)
Spot @ $9.92

With ROIC of -35%, FCF yield of -6.21%, and a Piotroski F-Score of 2/9, the company is burning cash with no earnings floor under a $735

Careful chasing SGMT at $9.92. With ROIC of -35%, FCF yield of -6.21%, and a Piotroski F-Score of 2/9, the company is burning cash with no earnings floor under a $735.7M market capitalization.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $8.23 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%